Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 4Recurrence 3Esophageal Squamous Cell Carcinoma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Melanoma 2Leukemia, Myeloid, Acute 2Endometrial Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Barrett Esophagus 2Adenocarcinoma Of Esophagus 2Tuberous Sclerosis 1Solid Tumors 1Refractory or Relapsed Solid Tumors 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoma, Follicular 1Lung Neoplasms 1Liver Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

darolutamide 1Rifampin 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Refractory or Relapsed Solid Tumors × Itraconazole × 1 year × Clear all
NCT07620041 2026-06-02

QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction

Qilu Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
48 enrolled
Other solid neoplasm

Refractory or Relapsed Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡